Y-mabs files for EU approval for pediatric cancer drug
On Tuesday, Danish biotech firm Y-mabs submitted an application to get approval for the cancer drug omburtamab, according to the firm.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
US-Danish Biotech firm Y-mabs, which is listed on US Stock Exchange Nasdaq, has submitted a new application for marketing authorization for a cancer treatment. This was revealed after the close of trading on Tuesday.
An HR expert points to increasing competition for skilled workers combined with their pandemic fatigue as factors behind initiatives like Novo Nordisk’s advanced salary talks, Genmab’s extra day off a month, and Bavarian Nordic’s gift of four vacation days.